1. Home
  2. ROMA vs NKTX Comparison

ROMA vs NKTX Comparison

Compare ROMA & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roma Green Finance Limited

ROMA

Roma Green Finance Limited

HOLD

Current Price

$5.40

Market Cap

134.6M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.26

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROMA
NKTX
Founded
2018
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.6M
132.8M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ROMA
NKTX
Price
$5.40
$2.26
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$13.25
AVG Volume (30 Days)
496.9K
676.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$1.31
52 Week High
$8.88
$2.81

Technical Indicators

Market Signals
Indicator
ROMA
NKTX
Relative Strength Index (RSI) 77.84 43.60
Support Level $2.05 $1.95
Resistance Level $8.88 $2.47
Average True Range (ATR) 0.86 0.19
MACD 0.36 -0.04
Stochastic Oscillator 53.75 4.10

Price Performance

Historical Comparison
ROMA
NKTX

About ROMA Roma Green Finance Limited

Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: